_(cropped).jpg){kind=link}
Nikola Vucevic
Career 1,041 G · 17,697 PTS · 17.0 PPG · 10.3 RPG · 2.9 APG
Seasons leading the NBA
1
17
Top-5 finishes
1
Title seasons
1
Categories led
2022
Best season
Spanning 2022–2022, peaking at 1 titles in 2022.
All-Time Standing
Against every player since 1951Among league leaders
- 192nd League titles 1
- 94th Top-5 finishes 17
Each rank is against the players who have achieved that thing at least once.
Career leaderboards
- 19th Defensive Rebounds 8,148
- 33rd Total Rebounds 10,707
- 44th Rebounds per Game 10.3
- 50th Offensive Rebounds 2,559
- 52nd Field Goals Made 7,524
- 90th Total Points 17,684
- 133rd Total Blocks 885
- 148th Effective FG Percentage 53.0%
- 174th Field Goal Percentage 49.7%
- 178th Points per Game 17.1
- 186th Three-Pointers Made 998
- 189th Turnovers 1,755
- 213th Blocks per Game 0.9
- 233rd Total Assists 3,025
- 264th Total Steals 860
- 310th True Shooting Percentage 55.0%
- 384th Free Throw Percentage 77.3%
- 436th Assists per Game 2.9
- 454th Three-Point Percentage 35.0%
- 500th Free Throws Made 1,638
All-time career totals, top 500 per category.
Where He Led
| Category | Titles | Best | Streak | Seasons |
|---|---|---|---|---|
| Defensive Rebounds | 1 | 1st | — | 2022-2023 744 2018-2019 #3 2020-2021 #2 2021-2022 #3 |
| Field Goals Made | — | #3 | — | 2020-2021 #3 |
| Total Rebounds | — | #2 | — | 2012-2013 #3 2018-2019 #3 2020-2021 #3 2022-2023 #2 |
| Rebounds per Game | — | #2 | — | 2012-2013 #2 |
Season Averages
16 seasons| Year | Team | GP | MPG | PTS | PPG | REB | RPG | AST | APG | STL | BLK | TOV | FG% | 3P% | FT% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2011-2012 | PHI | 51 | 15.9 | 283 | 5.5 | 246 | 4.8 | 31 | 0.6 | 20 | 34 | 33 | 45.0% | 37.5% | 52.9% |
| 2012-2013 | ORL | 77 | 33.2 | 1,008 | 13.1 | 917 | 11.9 | 143 | 1.9 | 61 | 79 | 141 | 51.9% | 0.0% | 68.3% |
| 2013-2014 | ORL | 57 | 31.8 | 811 | 14.2 | 626 | 11.0 | 104 | 1.8 | 60 | 47 | 112 | 50.7% | — | 76.6% |
| 2014-2015 | ORL | 74 | 34.2 | 1,428 | 19.3 | 810 | 10.9 | 147 | 2.0 | 54 | 54 | 148 | 52.3% | 33.3% | 75.2% |
| 2015-2016 | ORL | 65 | 31.3 | 1,181 | 18.2 | 576 | 8.9 | 179 | 2.8 | 53 | 70 | 123 | 51.0% | 22.2% | 75.3% |
| 2016-2017 | ORL | 75 | 28.8 | 1,096 | 14.6 | 779 | 10.4 | 208 | 2.8 | 76 | 74 | 117 | 46.8% | 30.7% | 66.9% |
| 2017-2018 | ORL | 57 | 29.5 | 939 | 16.5 | 523 | 9.2 | 191 | 3.4 | 56 | 62 | 109 | 47.5% | 31.4% | 81.9% |
| 2018-2019 | ORL | 80 | 31.4 | 1,665 | 20.8 | 960 | 12.0 | 307 | 3.8 | 81 | 89 | 159 | 51.8% | 36.4% | 78.9% |
| 2019-2020 | ORL | 62 | 32.2 | 1,215 | 19.6 | 673 | 10.9 | 222 | 3.6 | 54 | 47 | 88 | 47.7% | 33.9% | 78.4% |
| 2020-2021 | CHI | 70 | 33.5 | 1,639 | 23.4 | 817 | 11.7 | 269 | 3.8 | 65 | 48 | 126 | 47.7% | 40.0% | 84.0% |
| 2021-2022 | CHI | 73 | 33.1 | 1,288 | 17.6 | 804 | 11.0 | 236 | 3.2 | 70 | 71 | 136 | 47.3% | 31.4% | 76.0% |
| 2022-2023 | CHI | 82 | 33.5 | 1,447 | 17.6 | 903 | 11.0 | 265 | 3.2 | 60 | 57 | 139 | 52.0% | 34.9% | 83.5% |
| 2023-2024 | CHI | 76 | 34.3 | 1,370 | 18.0 | 801 | 10.5 | 254 | 3.3 | 50 | 60 | 120 | 48.4% | 29.4% | 82.2% |
| 2024-2025 | CHI | 73 | 31.2 | 1,349 | 18.5 | 735 | 10.1 | 256 | 3.5 | 61 | 52 | 119 | 53.0% | 40.2% | 80.5% |
| 2025-2026 | BOS | 64 | 28.4 | 965 | 15.1 | 537 | 8.4 | 213 | 3.3 | 39 | 41 | 85 | 49.3% | 36.9% | 82.8% |
| 2026-2027 | ORL | 5 | 9.2 | 13 | 2.6 | 11 | 2.2 | 6 | 1.2 | 0 | 3 | 2 | 38.5% | 25.0% | 50.0% |
| Career | — | 1,041 | 31.1 | 17,697 | 17.0 | 10,718 | 10.3 | 3,031 | 2.9 | 860 | 888 | 1,757 | 49.7% | 35.0% | 77.3% |